LEADER 01361nam  2200373Ia 450 
001 9910698838603321
005 20090521110736.0
035   $a(CKB)5470000002397481
035   $a(OCoLC)334535486
035   $a(EXLCZ)995470000002397481
100   $a20090521d2004      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $ecriteria for safety and efficacy evaluation of oxygen therapeutics as red blood cell substitutes
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research,$d[2004]
215   $ai, 17 pages $cdigital, PDF file
300   $aTitle from PDF title page (viewed on May 21, 2009).
300   $a"Draft guidance."
300   $a"October 2004".
517   $aGuidance for industry 
606   $aOxygen therapy$zUnited States$xEvaluation
606   $aErythrocytes$xTransfusion$zUnited States
615  0$aOxygen therapy$xEvaluation.
615  0$aErythrocytes$xTransfusion
712 02$aCenter for Biologics Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910698838603321
996   $aGuidance for industry$93434577
997   $aUNINA